Skip to content

Association of glucolipid metabolic characteristics and gut microbiota composition in patients with prediabetes and healthy controls

Association of glucolipid metabolic characteristics and gut microbiota composition in patients with prediabetes and healthy controls

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500101530
Enrollment
Unknown
Registered
2025-04-25
Start date
2025-05-01
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prediabetes

Interventions

Health control group:None

Sponsors

The First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Prediabetes Inclusion Criteria: 1. The diagnostic criteria for impaired fasting glucose (IFG) are fasting plasma glucose: 6.1mmol/L<FPG<7.0mmol/L, and plasma glucose < 7.8mmol/L 2 hours after glucose loading; 2. The diagnostic criteria for impaired glucose tolerance (IGT) are fasting plasma glucose < 7.0 mmol/L and plasma blood glucose between 7.8 mmol/L and 11.1 mmol/L 2 hours after glucose loading; 3. Or meet the conditions at the same time: between the ages of 18 and 65; Agree to participate in the study, sign the informed consent form. Inclusion criteria for healthy controls: Healthy control groups were matched 1:1 according to age, gender, and BMI.

Exclusion criteria

Exclusion criteria: 1. Patients with acute or chronic inflammatory or infectious diseases, or who receive antibiotics, probiotics, probiotics, or any other medication that may affect the intestinal microbiota in the first 3 months of inclusion; 2. Patients with persistent vomiting or suspected gastrointestinal obstruction; 3. Gastrectomy, gastric fundus folding, colostomy, and other digestive system surgeries; 4. Use of antibiotics in the past 3 months for a duration of 3 days or more; 5. Patients with moderate or severe renal impairment (blood creatinine > 2mg/dL or 177mmol/L), or abnormal liver function (ALT> twice the upper limit of average value); Moderate to severe chronic obstructive pulmonary disease; Patients with severe hypertension and cerebrovascular accidents; 6. Patients with severe cardiovascular and cerebrovascular, liver, kidney, and hematopoietic diseases; 7. Serious organic diseases, such as cancer, coronary heart disease, myocardial infarction, and stroke; 8. Suffering from infectious diseases such as tuberculosis and AIDS; 9. Excessive drinking (drinking more than 5 times a week, average 2 pairs of white wine or half a jin of yellow rice wine or more than 5 bottles of beer each time); 10. In the past three months, patients receiving medical treatment for the following diseases: cholecystitis, gastrointestinal ulcer, urinary tract infection, acute pyelonephritis, cystitis, hyperthyroidism, and other thyroid abnormalities; 11. Anemia: hemoglobin <10g/ dL; 12. Patients with physical disabilities or other reasons who are unable to take care of themselves, cannot clearly recall or answer questions, or have apparent dyskinesia; 13. Cannot guarantee sufficient time to participate in the project.

Design outcomes

Primary

MeasureTime frame
Intestinal microbial composition;

Secondary

MeasureTime frame
Blood biologic test results;Metabonomics;

Countries

China

Contacts

Public ContactNie Shaoping/Huang Xia

The First Affiliated Hospital of Nanchang University

ndyfy00382@ncu.edu.cn+86 151 6831 5971

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026